Page last updated: 2024-09-04

atazanavir sulfate and Coronary Disease

atazanavir sulfate has been researched along with Coronary Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dietz, B; Rajagopalan, R; Simpson, KN1
Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH1
Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN1
Coleman, CI; White, CM1
Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN1

Trials

1 trial(s) available for atazanavir sulfate and Coronary Disease

ArticleYear
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:2

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult

2013

Other Studies

4 other study(ies) available for atazanavir sulfate and Coronary Disease

ArticleYear
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
    Advances in therapy, 2009, Volume: 26, Issue:2

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States

2009
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Clinical drug investigation, 2007, Volume: 27, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors

2007
A comparison of different protease inhibitors on coronary heart disease risk.
    Connecticut medicine, 2007, Volume: 71, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Coronary Disease; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hyperlipidemias; Nelfinavir; Oligopeptides; Pyridines; Risk Factors

2007
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Clinical drug investigation, 2007, Volume: 27, Issue:12

    Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom

2007